Shares of Johnson & Johnson JNJ,
rose 0.9% in marketing on Monday as the company nears expected disclosure of interim results from a late-stage clinical trial evaluating its single-dose COVID-19 vaccine. J&J said in mid-December that it expects to share the findings of the Phase 3 trial by the end of January, which would make it the third company testing coronavirus vaccines in the US to disclose the results of a closely monitored Phase 3 trial. The other two vaccines, developed by BioNTech SE BNTX,
/ Pfizer Inc. PFE,
and Moderna Inc. MRNA,
are both mRNA-based vaccines that received Food and Drug Administration approval in December. J&J said in December that it will apply for an emergency permit in February for its adenovirus-based experimental vaccine, when the results are ready by the end of January. The company is expected to announce its fourth quarter and full year earnings on Tuesday. Shares of J & J are up 10.9% in the past year, while the S&P 500 SPX,
is up 15.6%.